Alliance Pharma Share Discussion Threads

[wad collector] 19/4/2024 21:04

Wouldn't want to brake hard in your car if you call a 1% rise traction!

[fatfish] 19/4/2024 15:30

gaining a little traction now :-)

[blackhorse23] 19/4/2024 14:51

Trading update for FY results were very good. Financial numbers are encouraging. If pays dividends next week share price will be 75p - 90p if not then 60p-65p . Likely reinstates dividends as indicated trading update. GROUP RETURNS TO PROFIT FROM 2023

[fatfish] 19/4/2024 13:57

Decided to have a little share buy, lets see what the results bring.

[blackhorse23] 19/4/2024 10:54

Last chance to BUY before next week results day surge, results will be very good

[maverick67] 18/4/2024 19:15

Well said... BH a clown and works at Billy Smarts Circus part time lol

[blackhorse23] 18/4/2024 18:43

Back to 120p after next week result. Revenues & profitability better than 2022

[blackhorse23] 18/4/2024 16:20

Looking bullish , 37.50 closing?

[mattboxy] 18/4/2024 15:44

37p down from120p in 2022!!!!! One things for sure nobody is switching money into here. Do you really think you can affect the share price asking a few PIs to buy!!Honestly!

[wad collector] 18/4/2024 14:20

Maverick I don't think he was referring to you, but this mornings heap of spamming:

Blackhorse23 - 18 Apr 2024 - 10:27:51 - 8536 of 8538 AudioBoom - Global Podcasts and Huge Markets - BOOM
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:26:15 - 3564 of 3565 Genedrive, A Game Changer for Point of Care Testing Market? - GDR
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:25:59 - 9803 of 9804 MyHealthChecked PLC to 100p - MHC
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:25:31 - 57529 of 57534 Avacta – Innovative and Disruptive Technologies for Global Health Markets - AVCT
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:25:12 - 3102 of 3105 Poolbeg Pharma - POLB
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION

Blackhorse23 - 18 Apr 2024 - 10:24:09 - 7221 of 7224 hVIVO plc - HVO
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:23:22 - 549 of 551 Redx Pharma PLC - REDX
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:22:48 - 68397 of 68399 COVID-19 - NCYT
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:22:13 - 1713 of 1714 Centrica 2021 - CNA
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 18 Apr 2024 - 10:21:31 - 6018 of 6019 AstraZeneca - AZN
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION

[blackhorse23] 18/4/2024 13:23

AlliancePharma will be publishing FY results on 23 April, details provided in its trading update in Jan "remain accurate", reported revenues £182.7m for 2023,up 6%

[maverick67] 18/4/2024 12:57

Oh shut up you moron!! Stop posting on other boards and il stop here

[tomzimerman] 18/4/2024 11:48

Can't be bothered with this anymore, life's too short, there's always another bus going higher and in different directions. I wish genuine holders well here and hope the results come good for those in already. A little bit of advice, whether you down vote me or not I won't be surprised but genuinely your posts put investors off and although you may think spamming every board with the same posts it has the opposite effect which has been plainly obvious. You do what you want take my advice or ignore it and carry on. Perhaps a more constructive balanced approach as you obviously do know the markets well would help Good luck

[blackhorse23] 18/4/2024 11:28

Financial summary for NEXT WEEK: The Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.

[blackhorse23] 18/4/2024 10:20

AlliancePharma has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEND +5% -PORTFOLIO BROADENED THROUGH ACQUISITION

[blackhorse23] 17/4/2024 22:37

Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance.

[maverick67] 17/4/2024 21:32

Next rns good sales but we have increased debt to 180 mil sorry no div as we have to pay some debt off

[maverick67] 17/4/2024 21:28

140 million in debt high interest rates no divi expected

[tomzimerman] 17/4/2024 13:40

Yes what was it 30-40 percent uplift on results day you told that poor jerry You and your mates can down vote me all you like, truths coming out for all to see soon.

[blackhorse23] 17/4/2024 10:45

APH most of the business outside UK , revenue & profits will be up by 10% on next week FY results according to last month trading update RNS

[tomzimerman] 17/4/2024 09:48

Yes actually some good news out the uk regarding the economy today, may make this attractive soon and help relieve debt burdens, I don't hold here and don't short stocks ever, however I am interested but will wait until after the results and see what the outlook from the company is on results day. Good luck to all holder expect black donkey who is obviously constantly trading this and spamming everyone and everywhere.

[blackhorse23] 17/4/2024 09:30

Bought the dips

[blackhorse23] 16/4/2024 17:06

You need medicine from alliance pharma for mental health